Comparative Pharmacology
Head-to-head clinical analysis: FUROSCIX versus LASIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUROSCIX versus LASIX.
FUROSCIX vs LASIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Furosemide inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium and chloride reabsorption, leading to increased diuresis.
Furosemide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption and increasing urinary output.
80 mg subcutaneously once daily via prefilled syringe. Maximum 80 mg/day. Administer as an adjunct to oral diuretic therapy.
20-80 mg IV or PO once or twice daily; maximum 600 mg/day IV or PO.
None Documented
None Documented
Terminal half-life 1.5-2 hours in healthy; prolonged to 4-8 hours in renal impairment (CrCl <30 mL/min) and 9-19 hours in anuria
Terminal elimination half-life is approximately 1.5-2 hours. In renal impairment (CrCl <20 mL/min), half-life may prolong to up to 2-4 hours; in end-stage renal disease or heart failure, may exceed 4 hours.
Renal (60-80% unchanged; glucuronide metabolites account for 10-20%); biliary/fecal (<10%)
Primarily renal excretion (50-80% as unchanged drug) via glomerular filtration and proximal tubular secretion; minor fecal elimination (<5%).
Category C
Category C
Loop Diuretic
Loop Diuretic